青霉素过敏脱标和抗生素过敏评估工具的回顾性研究。

IF 1.9 4区 医学 Q3 INFECTIOUS DISEASES
Ryoko Honda, Kazuhiro Ishikawa, Hiroki Ozawa, Emilie Louise Akiko Matsumoto-Takahashi, Nobuyoshi Mori
{"title":"青霉素过敏脱标和抗生素过敏评估工具的回顾性研究。","authors":"Ryoko Honda, Kazuhiro Ishikawa, Hiroki Ozawa, Emilie Louise Akiko Matsumoto-Takahashi, Nobuyoshi Mori","doi":"10.1016/j.jiac.2024.09.015","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It has been reported that 95 % of patients labeled as penicillin-allergic may be mislabeled. However, the process of delabeling has not advanced due to a shortage of allergy specialists capable of conducting accurate assessments. To address this issue, The Antibiotics Allergy Assessment Tool (AAAT) has been proposed as a tool to evaluate patients who can be delabeled by non-specialists.</p><p><strong>Objective: </strong>This study aims to identify patients who can be delabeled and to evaluate patients who are likely to be delabeled using AAAT.</p><p><strong>Methods: </strong>Patients admitted to the hospital between January 1, 2017, and December 31, 2021, with documented penicillin allergy labels were included in the study. Patients who demonstrated tolerance to labeled antibiotics or were labeled without explicit allergy declarations were defined as delabeling. Subsequently, patients who did not meet the criteria for delabeling were evaluated for their potential to be delabeled using the AAAT, retrospectively.</p><p><strong>Results: </strong>530 patients were selected, of which 62 (11.7 %) were delabeled. The AAAT evaluation of the remaining patients indicated that at least an additional 137 (25.8 %) patients could potentially be delabeled.</p><p><strong>Conclusion: </strong>The use of AAAT demonstrated the potential to delabel approximately third as many patients without the need for specialist evaluation. To promote broader delabeling efforts in the future, prospective studies should investigate the safety and effectiveness of evaluation tools such as the AAAT.</p>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool.\",\"authors\":\"Ryoko Honda, Kazuhiro Ishikawa, Hiroki Ozawa, Emilie Louise Akiko Matsumoto-Takahashi, Nobuyoshi Mori\",\"doi\":\"10.1016/j.jiac.2024.09.015\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>It has been reported that 95 % of patients labeled as penicillin-allergic may be mislabeled. However, the process of delabeling has not advanced due to a shortage of allergy specialists capable of conducting accurate assessments. To address this issue, The Antibiotics Allergy Assessment Tool (AAAT) has been proposed as a tool to evaluate patients who can be delabeled by non-specialists.</p><p><strong>Objective: </strong>This study aims to identify patients who can be delabeled and to evaluate patients who are likely to be delabeled using AAAT.</p><p><strong>Methods: </strong>Patients admitted to the hospital between January 1, 2017, and December 31, 2021, with documented penicillin allergy labels were included in the study. Patients who demonstrated tolerance to labeled antibiotics or were labeled without explicit allergy declarations were defined as delabeling. Subsequently, patients who did not meet the criteria for delabeling were evaluated for their potential to be delabeled using the AAAT, retrospectively.</p><p><strong>Results: </strong>530 patients were selected, of which 62 (11.7 %) were delabeled. The AAAT evaluation of the remaining patients indicated that at least an additional 137 (25.8 %) patients could potentially be delabeled.</p><p><strong>Conclusion: </strong>The use of AAAT demonstrated the potential to delabel approximately third as many patients without the need for specialist evaluation. To promote broader delabeling efforts in the future, prospective studies should investigate the safety and effectiveness of evaluation tools such as the AAAT.</p>\",\"PeriodicalId\":16103,\"journal\":{\"name\":\"Journal of Infection and Chemotherapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Infection and Chemotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jiac.2024.09.015\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jiac.2024.09.015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

背景:据报道,95% 被贴上青霉素过敏标签的患者可能是被误贴的。然而,由于缺乏能够进行准确评估的过敏专科医生,取消标签的进程并未取得进展。为了解决这一问题,有人提出了抗生素过敏评估工具(AAAT),作为评估非专科医生可以解除标签的患者的工具:本研究旨在使用 AAAT 确定可被取消标签的患者,并评估可能被取消标签的患者:研究对象包括 2017 年 1 月 1 日至 2021 年 12 月 31 日期间入院并有青霉素过敏标签记录的患者。对标签抗生素表现出耐受性或标签上没有明确过敏声明的患者被定义为脱标签患者。随后,对不符合脱标标准的患者使用 AAAT 进行回顾性评估,以确定其是否有可能脱标:结果:共选取了 530 名患者,其中 62 人(11.7%)被解除标记。对其余患者的 AAAT 评估表明,至少还有 137 名患者(25.8%)有可能被解除标记:结论:AAAT 的使用表明,无需专家评估,就有可能对大约三分之一的患者进行脱标。为促进未来更广泛的脱标工作,前瞻性研究应调查 AAAT 等评估工具的安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool.

Background: It has been reported that 95 % of patients labeled as penicillin-allergic may be mislabeled. However, the process of delabeling has not advanced due to a shortage of allergy specialists capable of conducting accurate assessments. To address this issue, The Antibiotics Allergy Assessment Tool (AAAT) has been proposed as a tool to evaluate patients who can be delabeled by non-specialists.

Objective: This study aims to identify patients who can be delabeled and to evaluate patients who are likely to be delabeled using AAAT.

Methods: Patients admitted to the hospital between January 1, 2017, and December 31, 2021, with documented penicillin allergy labels were included in the study. Patients who demonstrated tolerance to labeled antibiotics or were labeled without explicit allergy declarations were defined as delabeling. Subsequently, patients who did not meet the criteria for delabeling were evaluated for their potential to be delabeled using the AAAT, retrospectively.

Results: 530 patients were selected, of which 62 (11.7 %) were delabeled. The AAAT evaluation of the remaining patients indicated that at least an additional 137 (25.8 %) patients could potentially be delabeled.

Conclusion: The use of AAAT demonstrated the potential to delabel approximately third as many patients without the need for specialist evaluation. To promote broader delabeling efforts in the future, prospective studies should investigate the safety and effectiveness of evaluation tools such as the AAAT.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Infection and Chemotherapy
Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY
CiteScore
4.10
自引率
4.50%
发文量
303
审稿时长
47 days
期刊介绍: The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信